Safety of SC Daratumumab in the Treatment of Plasma|Cell Disorders

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders

They recommend monitoring for systemic reactions for 4 hours after the injection of daratumumab on cycle 1, day 1 for daratumumab-naïve patients and ...

Safety of subcutaneous daratumumab in the treatment of plasma ...

Secondary outcomes include timing and severity of IRRs based on CTCAE version 4.0. Results: A total of 82 patients received SC Dara during the ...

Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal ...

Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life ...

Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal ...

Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an intravenous ...

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders

METHODS: This single-center, retrospective study included patients with multiple myeloma and/ or light-chain amyloidosis who were receiving SC daratumumab at ...

Subcutaneous Daratumumab is Safe and Tolerable in Multiple ...

Findings from the phase 3 PERSEUS study found the safety profile of D-VRd in newly diagnosed multiple myeloma to be in line with the known profiles of the ...

Safety and Efficacy of Subcutaneous Daratumumab | TCRM

SC daratumumab appears to deliver the same disease benefit as IV daratumumab to patients with decreased infusion-related reactions (IRRs), decreased time for ...

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders

Title: Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders: A Single-Center Experience. ; Language: English ; Authors: Jung Kye · Patel, Samit Seyer ...

Safety of subcutaneous daratumumab in the treatment of plasma ...

Request PDF | Safety of subcutaneous daratumumab in the treatment of plasma-cell disorders: A single-center experience. | e20007 Background: Daratumumab ...

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders: A Single-Center Experience. · Jung Kye; Patel, Samit; Seyer, Maggie; Eun-Jeong Kim; Hewitt, ...

Safety, tolerability, and response rates of daratumumab in relapsed ...

Daratumumab, a monoclonal CD38 antibody, is approved in the treatment of myeloma, but its efficacy and safety in light-chain (AL) amyloidosis ...

Subcutaneous daratumumab in patients with relapsed or refractory ...

Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of ...

(PDF) Safety of Subcutaneous Daratumumab in Anti-CD38 ...

In this multicenter retrospective real-life experience, we provided evidence for the safety of subcutaneous daratumumab in plasma cell disorders ...

Evaluation of administration-related reactions with subcutaneous ...

Daratumumab-hyaluronidase-fihj (Dara-SQ) is frequently used in the treatment of plasma cell disorders and is associated with improved ...

Eliminating the monitoring period with subcutaneous daratumumab

In the phase 3 COLUMBA trial, SC daratumumab yielded a similar overall response rate (41% vs. 37%) and fewer infusion related reactions (13% vs.

Short observation time after subcutaneous Daratumumab ...

Significant reduction in SC daratumumab observation time is not only safe for patients but also effective in reducing infusion chair time. This in turn leads to ...

DARZALEX® (daratumumab)-SC based quadruplet regimen ...

Daratumumab is the only CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma.2 Daratumumab SC is ...

Daratumumab-Based Treatment for Immunoglobulin Light-Chain ...

Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease. Methods. We randomly assigned patients with newly diagnosed ...

Transition from Intravenous to Subcutaneous Daratumumab ...

Introduction. Daratumumab is an anti-CD38 monoclonal antibody widely used for treating patients with newly diagnosed or relapsed/refractory multiple myeloma.

Subcutaneous Daratumumab Comparable to Intravenous Treatment ...

The study also showed an improved safety profile with SC versus IV daratumumab ... Usmani, MD, FACP, chief of the Plasma Cell Disorders, and ...